Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Lenvatinib + losartan

"Patients will receive a combination of lenvatinib and losartan at the same time after surgery for treatment cycles once daily (lenvatinib and losartan).~Adjuvant therapy will be started within 2-6 weeks after surgery for a period of time to evaluate the effect of different treatment regimens on reducing tumor recurrence and improving survival.~lenvatinib: orally once daily according to standard dosing guidelines, starting postoperatively.~losartan: 50mg losartan potassium tablets orally once daily starting postoperatively."

All Listed Sponsors
collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

Shaanxi Provincial People's Hospital

OTHER

collaborator

Affiliated Hospital of Qinghai University

OTHER

lead

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER